There are four coronavirus vaccines in late-stage studies — here’s how they differ
Johnson & Johnson’s investigational COVID-19 vaccine entered Phase 3 clinical trials this week, making it the fourth vaccine candidate in the U.S. to do so and providing additional details that can help investors differentiate the pool of late-stage coronavirus vaccines.
Shares of J&J JNJ, 0.76% were up 0.3% in trading on Friday, two days after the health care giant announced it had dosed the first of an estimated 60,000 participants in the Phase 3 trial for Ad26.COV2.S, which is also referred to as JNJ-78436735.
J&J’s vaccine candidate joins a group...